Clinical Research Directory

Key Inclusion Criteria: * Determined by the Investigator to be not eligible for auto-SCT * Documented newly diagnosed multiple myeloma (NDMM) according to IMWG diagnostic criteria * Measurable disease at screening per IMWG: 1. Serum M-protein level ≥ 1.0 g/dL; or 2. Urine M-protein level ≥ 200 mg/24 hours; or 3. Serum free light chain (FLC) ≥ 10 mg/dL (100 mg/L) and abnormal serum FLC ratio * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Adequate hematological function * Adequate renal, hepatic, pulmonary, and cardiac function Key Exclusion Criteria: * Any prior anti-MM therapy (including B-cell maturation antigen (BCMA)-directed therapy, CAR T-cell therapy, or genetically modified cells), with the exception of protocol-specified anti-MM stabilizing therapy and palliative radiation * Central nervous system (CNS) or meningeal involvement of MM * History of or active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or amyloidosis * Active malignancy (other than MM) requiring ongoing treatment for disease control within the last 24 months. * Prior allogeneic stem cell transplant * Any prior systemic treatment or radiotherapy treatment for any cancer other than MM within 24 months before randomization. * Live vaccine ≤ 4 weeks before randomization * Presence or suspicion of infection that is uncontrolled * History or presence of intracranial or CNS disorders, or CNS neoplasms (benign and malignant) * Females who are pregnant or breastfeeding * Females of childbearing potential who are not willing to use a highly effective method of contraception from the time of informed consent through the protocol-specified duration * Contraindication to fludarabine or cyclophosphamide * History of allergy or hypersensitivity to any trial agent or trial drug components * Life expectancy \< 12 weeks Note: Other protocol defined Inclusion/Exclusion criteria may apply.